Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan balsalazide
disodium 750 mg capsules and Salix Colazal® 750 mg capsules following a single, oral 2250 mg
(3 x 750 mg) dose administration under fasting conditions.